Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
Aurélien Marabelle, Marwan Fakih, Juanita Lopez, Manisha H. Shah, Ronnie Shapira‐Frommer, Kazuhiko Nakagawa, Hyun Cheol Chung, Hedy L. Kindler, José A. López-Martín, Wilson H. Miller, Antoîne Italiano, Steven Kao, Sarina A. Piha‐Paul, Jean‐Pierre Delord, Robert R. McWilliams, David Fabrizio, Deepti Aurora-Garg, Lei Xu, Fan Jin, Kevin Norwood, Yung‐Jue Bang
Topics & Concepts
MedicinePembrolizumabInternal medicineResponse Evaluation Criteria in Solid TumorsOncologyCohortMesotheliomaBiomarkerClinical endpointProspective cohort studyCancerProgressive diseaseDiseaseImmunotherapyPathologyClinical trialBiochemistryChemistryCancer Immunotherapy and BiomarkersMultiple and Secondary Primary CancersColorectal and Anal Carcinomas